

Contact: Sanjeev Luther
Chief Business Officer, Cornerstone Pharmaceuticals, Inc.
Sanjeev@cornerstonepharma.com

Kara Golub
Vice President, JFK Communications, Inc.
609-456-0822
kgolub@jfkhealth.com

Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017

Biotech Showcase™ Occurs Concurrently to the 35th Annual JP Morgan Healthcare Conference - an Ideal Venue for Cornerstone Pharmaceuticals to Present its Exciting Corporate Vision and Unique Oncology Therapeutic Platform

CRANBURY, NEW JERSEY (December 22, 2016) –

WHAT: Cornerstone Pharmaceuticals will present to investors and biopharmaceutical executives from around the world. The 9th Annual Conference Biotech Showcase™ is one of the largest annual healthcare conferences around the world and will take place in San Francisco concurrently to the J.P. Morgan 35th Annual Healthcare Conference. Members of Cornerstone's management team will present information on its Altered Energy Metabolism Directed (AEMD) platform, update on clinical trials for its lead compound CPI-613, and future strategy.

Interviews prior and during the conference available upon request:

Presenters:

- **Sanjeev Luther**, Chief Operating Officer, Cornerstone Pharmaceuticals
- **Timothy S. Pardee, MD, PhD**, Chief Oncologist, Cornerstone Pharmaceuticals

Board Members:

- **Howard Jonas**, Chairman of the Board, Cornerstone Pharmaceuticals
- **Jean-Pierre Sommadossi, PhD**, Principal Founder, Chairman and CEO of Atea Pharmaceuticals, Vice Chairman of Cornerstone Pharmaceuticals Board of Directors

WHERE: 9th Annual Conference Biotech Showcase, Hilton San Francisco Union Square, San Francisco, California

WHEN: January 11, 2016, 2:30 – 3:00pm PT

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). www.cornerstonepharma.com.

###